Abstract 531P
Background
Tumor Treating Fields (TTFields) therapy uses electric fields to disrupt processes critical for cancer cell survival. TTFields therapy delivered by a wearable, portable device is approved in several counties for the treatment of newly diagnosed and recurrent glioblastoma (GBM), including Germany, Austria, Switzerland (DACH) and the US, and is under investigation for other tumour types.
Methods
Two surveys (independently developed and administered) were distributed (mail and online) in DACH and the US to patients/caregivers using TTFields (Optune(R); Novocure(R) GmbH, device manufacturer) as therapy for GBM.
Results
Between 1 January–31 December 2022, 545 (DACH) and 1282 (US) patients/caregivers returned surveys (response rates of 43% and 27%, respectively). In DACH, 43% had recently initiated therapy (“new starters”; 66% were male, 55% were ≥60 yrs of age). In the US, 31% of responses were from new starters; 69% were male and 63% were ≥60 yrs. Respondents with TTFields usage of >6 months (long-term users) accounted for 21% of DACH and 29% of US surveys; most were male (59% in DACH; 65% in US), and around half were ≥60 yrs of age (40% in DACH; 55% in US). Overall satisfaction (very satisfied, satisfied, mixed, less satisfied or dissatisfied) with TTFields was high; most respondents indicated they were very satisfied or satisfied (82% and 61% of new starters, and 67% and 74% of long-term users, in DACH and the US, respectively). Amongst long-term users, most noted that using TTFields required changes to daily life (63% DACH; 57% US). Frequently mentioned changes related to skin irritation, device handling, and impact of weight/portability on lifestyle. Despite this, the majority (74% in DACH; 73% in US) of long-term TTFields users/caregivers would recommend the treatment for GBM.
Conclusions
Surveys returned in DACH and the US showed the population of TTFields therapy users was representative of patients with GBM. Users from both surveys had a high level of satisfaction with the therapy and mostwould recommend it to others. Any potential concerns regarding device handling/portability can perhaps be mitigated by increased educational and communication efforts.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Novocure.
Funding
Novocure.
Disclosure
E.T. Batzianouli, R. Adams, H. Johnson, P.G. Gwyn, H.I. Abdullah: Financial Interests, Personal, Full or part-time Employment: Novocure; Financial Interests, Personal, Stocks/Shares: Novocure.
Resources from the same session
622P - Evaluation of the metastatic colorectal cancer score (mCCS) in predicting outcome for patients with RAS wild type metastatic colorectal cancer (mCRC) treated with first-line (1L) panitumumab (PAN) plus FOLFIRI/FOLFOX: Updated interim results of the non-interventional study VALIDATE
Presenter: Marcel Reiser
Session: Poster session 10
623P - VIC regimen (vemurafenib/irinotecan/cetuximab) versus bevacizumab plus chemotherapy as first-line treatment for BRAF V600E-mutated advanced colorectal cancer
Presenter: Yijiao Chen
Session: Poster session 10
624P - Tolerability and safety of vemurafenib, cetuximab combined with camrelizumab for BRAF V600E-mutated /MSS metastatic colorectal cancer
Presenter: Meng Qiu
Session: Poster session 10
625P - Efficacy and safety of the combination of encorafenib and cetuximab in patients with BRAF V600E mutated metastatic colorectal cancer: An AGEO real-world multicentre study
Presenter: Claire Gallois
Session: Poster session 10
626P - Mucinous differentiation (MD) as predictor of response in BRAF-V600E mutated metastatic colorectal cancer (mCRC) treated with BRAF inhibitors (BRAFi) combinations
Presenter: Francisco Javier Ros Montana
Session: Poster session 10